Autopsy report · NCT02612428

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

“VTL-308 failed to meet its primary endpoint, all follow up studies were terminated”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 8 months before it stopped.
• 151 participants enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Vital Therapies, Inc.

Sponsor type

Industry

Conditions

Acute Alcoholic Hepatitis

Interventions

ELAD System; Standard of Care (Control)

Participants

151

Sites

44

Countries

Austria, Germany, Ireland, Spain, United Kingdom, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.